Sugi Predict

Sugi Predict / Targets / PSMB10

PSMB10

Proteasome subunit beta type-10 · P40306 · PSMB10 on Sugi Atlas →

28,644 patent compounds predicted against PSMB10, 19,452 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL464435 SCHEMBL464435 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL234139 SCHEMBL234139 0.71 11/20
Leucine Leucine (SCHEMBL1041561) 0.63 11/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20

Clinical trials — most relevant to PSMB10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Colchicine for Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy nanUNKNOWN
Cholesterol and Statin in Healthy Adults nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE) nanACTIVE_NOT_RECRUITING
Dysfunctions of Human Muscle Stem Cells in Sepsis nanCOMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMB10 binder may also engage these)

ProteinNameSimilarity
Q4KM35 — 1.000 Q4KM35 →
Q3T0T1 — 0.999 Q3T0T1 →
O35955 — 0.994 O35955 →
P70195 — 0.994 P70195 →
Q09841 — 0.992 Q09841 →
A1XQU1 — 0.992 A1XQU1 →
Q5REN2 — 0.991 Q5REN2 →
Q3T0X5 — 0.990 Q3T0X5 →
P28064 — 0.990 P28064 →
PSMB7 Proteasome subunit beta type-7 0.989 landscape →
PSMA1 Proteasome subunit alpha type-1 0.989 landscape →
P28075 — 0.988 P28075 →
O16811 — 0.988 O16811 →
O44156 — 0.987 O44156 →
Q27488 — 0.987 Q27488 →
PSMA2 Proteasome subunit alpha type-2 0.987 landscape →
Q3T112 — 0.987 Q3T112 →
O42265 — 0.987 O42265 →
O23712 — 0.987 O23712 →
Q2TBP0 — 0.987 Q2TBP0 →
Q9JHW0 — 0.987 Q9JHW0 →
Q0J006 — 0.986 Q0J006 →
O55234 — 0.986 O55234 →
P52428 — 0.986 P52428 →
Q7DLS1 — 0.986 Q7DLS1 →
Q24178 — 0.986 Q24178 →
P30656 — 0.986 P30656 →
PSMB5 Proteasome Macropain subunit MB1 0.986 landscape →
Q4R3H2 — 0.986 Q4R3H2 →
O14250 — 0.986 O14250 →